Therapie des Morbus Crohn: Step-up oder Top-down?

Schlüsselwörter

Morbus Crohn - Infliximab - Azathioprin - opportunistische Infektionen - Lymphom - Step-up - Top-down

Keywords

Crohn's disease - infliximab - azathioprine - opportunistic infections - lymphoma - step-up - top-down

Literatur

• 1 Andus T. et al . [Suspected cases of severe side effects after infliximab (Remicade) in Germany].  Med Klin . 2003;  98 429-436
• 2 Baert F. et al . Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease.  Gastroenterology. 2010;  138 463-468
• 3 Beaugerie L. et al . Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.  Lancet. 2009;  374 1617-1625
• 4 Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD.  Nat Clin Pract Gastroenterol Hepatol. 2007;  4 78-91
• 5 Bongartz T, Sutton A J, Sweeting M J, Buchan I, Matteson E L, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies.  JAMA. 2006;  295 2275-2285
• 6 Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease.  Gut. 1995;  37 674-678
• 7 Carmona L. et al . Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.  Arthritis Rheum. 2005;  52 1766-1772
• 8 Colombel J F. et al . The safety profile of infliximab in patients with Crohn’s disease.  Gastroenterology. 2004;  126 19-31
• 9 Colombel J F. et al . Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease.  Gastroenterology. 2007;  132 52-65
• 10 Colombel J F. et al . Infliximab, azathioprine, or combination therapy for Crohn’s disease.  N Engl J Med. 2010;  362 1383-1395
• 11 Cosnes J. et al . Long-term evolution of disease behavior of Crohn’s disease.  Inflamm Bowel Dis. 2002;  8 244-250
• 12 Cosnes J. et al . Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery.  Gut. 2005;  54 237-241
• 13 Cullen G, Keegan D, Mulcahy H E, O’Donoghue D P. A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn’s disease.  Clin Gastroenterol Hepatol. 2009;  7 323-328
• 14 D’Haens G. et al . Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease.  Lancet. 2008;  371 660-667
• 15 Faubion Jr W A. et al . The natural history of corticosteroid therapy for inflammatory bowel disease.  Gastroenterology. 2001;  121 255-260
• 16 Frøslie K F. et al . Mucosal healing in inflammatory bowel disease.  Gastroenterology. 2007;  133 412-422
• 17 Gasche C. et al . A simple classification of Crohn’s disease.  Inflamm Bowel Dis. 2000;  6 8-15
• 18 Hanauer S B. et al . Maintenance infliximab for Crohn’s disease.  Lancet. 2002;  359 1541-1549
• 19 Ho G T. et al . The efficacy of corticosteroid therapy in inflammatory bowel disease.  Aliment Pharmacol Ther. 2006;  24 319-330
• 20 Hoffmann J C. et al . [Clinical practice guideline on diagnosis and treatment of Crohn’s disease].  Z Gastroenterol. 2008;  46 1094-1146
• 21 Keane J. et al . Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.  N Engl J Med. 2001;  345 1098-1104
• 22 Ljung T. et al . Infliximab in inflammatory bowel disease.  Gut. 2004;  53 849-853
• 23 Louis E. et al . Behaviour of Crohn’s disease according to the Vienna classification.  Gut. 2001;  49 777-782
• 24 Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease.  Gastroenterology. 2000;  119 895-902
• 25 Modigliani R. et al . Clinical, biological, and endoscopic picture of attacks of Crohn’s disease.  Gastroenterology. 1990;  98 811-818
• 26 Moum B. et al . Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn’s disease.  Scand J Gastroenterol. 1997;  32 1005-1012
• 27 Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease.  Gut. 1994;  35 360-362
• 28 Oostenbrug L E. et al . Clinical outcome of Crohn’s disease according to the Vienna classification.  Eur J Gastroenterol Hepatol. 2006;  18 255-261
• 29 Rahier J F. et al . European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.  J Crohn’s Dis Colitis. 2009;  3 47-91
• 30 Ramadas A V. et al . Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986 – 2003).  Gut,. epub 21.7.2010 ; 
• 31 Romberg-Camps M J. et al . Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease.  Am J Gastroenterol. 2009;  104 371-383
• 32 Schreiber S. et al . Maintenance therapy with certolizumab pegol for Crohn’s disease.  N Engl J Med. 2007;  357 239-250
• 33 Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease.  Gut. 2008;  57 1639-1641
• 34 Silverberg M S. et al . Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease.  Can J Gastroenterol. 2005;  19 Suppl A 5-36
• 35 Toruner M. et al . Risk factors for opportunistic infections in patients with inflammatory bowel disease.  Gastroenterology. 2008;  134 929-936
• 36 Veloso F T, Ferreira J T, Barros L, Almeida S. Clinical outcome of Crohn’s disease.  Inflamm Bowel Dis. 2001;  7 306-313
• 37 Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.  Arthr Rheum. 2007;  56 1433-1439
• 38 Wolters F L. Phenotype at diagnosis predicts recurrence rates in Crohn’s disease.  Gut. 2006;  55 1124-1130